Neuraly

Executive Summary

Neuraly is a private biopharmaceutical company based in Cambridge, MA, focused on developing novel small-molecule therapies for neurodegenerative diseases, specifically Alzheimer's and Parkinson's. Founded in 2016, the company has advanced to Phase 2 clinical stage, leveraging proprietary pathways discovered by its founders. Neuraly aims to redefine treatment paradigms by targeting underlying disease mechanisms rather than just symptoms, with the potential to modify disease progression. While specific pipeline details are not publicly disclosed, the company's progress to Phase 2 suggests promising preclinical and early clinical data. As a private entity, Neuraly has not disclosed total funding or valuation, but its continued advancement indicates sustained investor confidence. The company's strategic location in Cambridge provides access to top-tier scientific talent and partnerships.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim data readout for lead Alzheimer's candidate35% success
• Q2 2027Series C financing round to support Phase 3 preparation50% success
• Q3 2027Strategic collaboration with a major pharma company for Parkinson's program40% success